Institute of Biomedical Sciences, Academia Sinica, Taipei City, 115, Taiwan.
Institute of Translational Medicine and New Drug Development, China Medical University, Taichung City, 404, Taiwan.
Exp Mol Med. 2023 Sep;55(9):1872-1884. doi: 10.1038/s12276-023-01021-0. Epub 2023 Sep 11.
A dysregulated type 2 immune response is one of the fundamental causes of allergic asthma. Although Th2 cells are undoubtedly central to the pathogenesis of allergic asthma, the discovery of group 2 innate lymphoid cells (ILC2s) has added another layer of complexity to the etiology of this chronic disease. Through their inherent innate type 2 responses, ILC2s not only contribute to the initiation of airway inflammation but also orchestrate the recruitment and activation of other members of innate and adaptive immunity, further amplifying the inflammatory response. Moreover, ILC2s exhibit substantial cytokine plasticity, as evidenced by their ability to produce type 1- or type 17-associated cytokines under appropriate conditions, underscoring their potential contribution to nonallergic, neutrophilic asthma. Thus, understanding the mechanisms of ILC2 functions is pertinent. In this review, we present an overview of the current knowledge on ILC2s in asthma and the regulatory factors that modulate lung ILC2 functions in various experimental mouse models of asthma and in humans.
2 型免疫反应失调是引起过敏性哮喘的根本原因之一。虽然 Th2 细胞无疑是过敏性哮喘发病机制的核心,但 2 类固有淋巴细胞(ILC2)的发现为这种慢性疾病的病因又增添了一层复杂性。通过固有 2 型反应,ILC2 不仅有助于气道炎症的启动,还协调固有免疫和适应性免疫其他成员的募集和激活,进一步放大炎症反应。此外,ILC2 表现出显著的细胞因子可塑性,这表现在它们在适当条件下能够产生 1 型或 17 型相关细胞因子,突出了它们对非过敏性、中性粒细胞性哮喘的潜在贡献。因此,了解 ILC2 功能的机制至关重要。在这篇综述中,我们概述了目前关于哮喘中 ILC2 的知识,以及调节因子在各种哮喘实验小鼠模型和人类中调节肺 ILC2 功能的机制。